- Home
- DOMH vs KZIA Comparison
DOMH vs KZIA Comparison
Compare DOMH & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DOMH
- KZIA
- Stock Information
- Founded
- DOMH 1967
- KZIA 1994
- Country
- DOMH United States
- KZIA Australia
- Employees
- DOMH N/A
- KZIA N/A
- Industry
- DOMH Biotechnology: Pharmaceutical Preparations
- KZIA Biotechnology: Pharmaceutical Preparations
- Sector
- DOMH Health Care
- KZIA Health Care
- Exchange
- DOMH Nasdaq
- KZIA Nasdaq
- Market Cap
- DOMH 94.0M
- KZIA 9.0M
- IPO Year
- DOMH N/A
- KZIA 1999
- Fundamental
- Price
- DOMH $5.98
- KZIA $8.01
- Analyst Decision
- DOMH
- KZIA Strong Buy
- Analyst Count
- DOMH 0
- KZIA 2
- Target Price
- DOMH N/A
- KZIA $14.00
- AVG Volume (30 Days)
- DOMH 314.7K
- KZIA 137.3K
- Earning Date
- DOMH 11-07-2025
- KZIA 11-14-2025
- Dividend Yield
- DOMH 8.23%
- KZIA N/A
- EPS Growth
- DOMH N/A
- KZIA N/A
- EPS
- DOMH N/A
- KZIA N/A
- Revenue
- DOMH $52,811,000.00
- KZIA $1,549,158.00
- Revenue This Year
- DOMH N/A
- KZIA N/A
- Revenue Next Year
- DOMH N/A
- KZIA $49.25
- P/E Ratio
- DOMH N/A
- KZIA N/A
- Revenue Growth
- DOMH 455.38
- KZIA 248983.08
- 52 Week Low
- DOMH $0.83
- KZIA $2.86
- 52 Week High
- DOMH $13.58
- KZIA $39.05
- Technical
- Relative Strength Index (RSI)
- DOMH 48.37
- KZIA 49.51
- Support Level
- DOMH $5.61
- KZIA $7.60
- Resistance Level
- DOMH $7.18
- KZIA $8.88
- Average True Range (ATR)
- DOMH 0.47
- KZIA 0.59
- MACD
- DOMH -0.01
- KZIA 0.05
- Stochastic Oscillator
- DOMH 22.29
- KZIA 35.62
About DOMH Dominari Holdings Inc.
Dominari Holdings Inc through its various subsidiaries, is currently engaged in wealth management, investment banking, securities sales and trading and asset management. The company operates in two reportable business segments: Dominari Financial and Legacy AIkido. The Dominari Financial reportable business segment represents the Company's broker-dealer business, which is composed of mostly underwriting and transactional service activities. The Legacy AIkido reportable business segment includes Aikido Labs, which manages the investments holdings of the legacy entity. It generates the majority of its revenue from the Dominari Financial segment.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.